Whalesbook
Bhagiradha Chemicals & Industries Limited: Q3FY26 Earnings Analysis
Bhagiradha Chemicals & Industries Limited has presented its Q3 and 9MFY26 investor update, revealing a mixed performance characterized by strong year-on-year (YoY) gains in the latest quarter, but a notable sequential decline and significant underlying concerns.
📉 The Financial Deep Dive
The Numbers: For the third quarter ended December 31, 2025 (Q3FY26), Bhagiradha Chemicals reported an 11% YoY increase in revenue to ₹114.0 crore. Profit After Tax (PAT) witnessed a healthy 28% YoY jump to ₹4.6 crore. EBITDA also surged by a significant 49% YoY to ₹13.7 crore. Gross margins expanded by 311 basis points YoY to 43.0%, leading to an improved EBITDA margin of 12.0% for the quarter.
However, on a sequential (QoQ) basis, Q3FY26 revenues saw a substantial decline of 19% from ₹140.1 crore in Q2FY26, with EBITDA and PAT also decreasing by 9% and 16% respectively, a trend management attributed to typical seasonality.
For the nine-month period of FY26 (9MFY26), revenue grew 19% YoY to ₹377.8 crore, with EBITDA rising 22% YoY to ₹37.7 crore. PAT, however, saw a marginal decrease of 4% YoY to ₹14.1 crore.
The full year FY25 saw revenues at ₹441 crore, with significantly lower profitability metrics: EBITDA at ₹14 crore (3.1% margin) and PAT at ₹13.9 crore (3.1% margin), impacted by unfavorable market conditions.
The Quality: While Q3FY26 margins show a marked improvement, the 9MFY26 EBITDA margin stood at 10.0%, and FY25 was particularly weak at 3.1%. A critical red flag is the dramatic increase in working capital days, which ballooned from 99 days in FY22 to a concerning 170 days in FY25. This indicates a significant strain on liquidity, potentially due to rising inventory levels or slower receivables collection. The company maintains a low Debt-to-Equity ratio of 0.1 (FY25), but this is against the backdrop of substantial equity infusion.
🚀 Strategic Analysis & Impact
The Event: The company is undertaking a large-scale expansion program of approximately ₹800 crore through its wholly-owned subsidiary, Bheema Fine Chemicals. This involves Phase 1B (₹346 crore, commenced Q3 FY26) and Phase 2 (₹350 crore, expected by Q2 FY28). The funding involves conversion of loans to equity and a recent preferential issuance of warrants worth ₹340 crore.
The Edge: The expansion, if executed successfully, aims to increase capacity utilization and position the company for its full revenue potential. Management targets a revenue increase of five times the current level within 6 to 7 years. The recent launch of a new herbicide product and commissioning of a solar plant are incremental positives.
Peer Context: While specific competitor order wins or expansions are not detailed, the chemical sector is generally characterized by significant capital expenditure cycles and the need for continuous product innovation and capacity expansion to maintain market share.
🚩 Risks & Outlook
Specific Risks: The most significant risk highlighted is the ballooning working capital days, which could tie up substantial cash and impact operational flexibility. The large ₹800 crore expansion program carries execution risks, cost overruns, and potential delays. The historical decline in Return on Capital Employed (ROCE) from 18% in FY21 to 3% in FY25, and Return on Equity (ROE) from 15.0% to 2.0% (attributed by management to funds deployed in subsidiary projects), signals past underperformance that needs to be reversed.
The Forward View: Investors will be watching for the successful ramp-up of the Bheema facility in FY27, which management believes will drive stronger growth and margin improvement. The ability to manage the increased working capital efficiently and execute the expansion plan within budget and timelines will be crucial for the company's future trajectory. The long-term vision of five-fold revenue growth is ambitious and hinges on sustained operational efficiency and market demand.